The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 551-557

  Thallinger, C ^a   Urbauer, E ^a   Lackner, E ^a   Graselli, U ^a   Kostner, K ^a   Wolzt, M ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HMG CoA reductase inhibitor; LDL oxidation; Statins

Indexed keywords

ALKADIENE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 29444443126     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43551     Document Type: Article

References (20)

1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS 1998 Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138: 271-280
2. Chajes V, Sattler W, Stultschnig M, Kostner GM 1996 Photometric evaluation of lipid peroxidation products in human plasma and copper oxidized low density lipoproteins: correlation of different oxidation parameters. Atherosclerosis 121: 193-203
3. Collins R, Peto R, Armitage J 2002 The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 56: 53-56
4. Esterbauer H, Cheeseman KH 1990 Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186: 407-421
5. Girona J, La Ville AE, Sola R, Plana N, Masana L 1999 Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83: 846-851
6. Hoffman R, Brook GJ, Aviram M 1992 Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 93: 105-113
7. Kleinveld HA, Naber AH, Stalenhoef AF, Demacker PN 1993 Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. Free Radic Biol Med 15: 273-280
8. Lennernas H, Fager G 1997 Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32: 403-425
9. Mackness M, Rossouw J 2002 The Heart Protection Study: death knell for the oxidation theory of atherosclerosis? Curr Opin Lipidol 13: 355
10. Rosenson RS 2004 Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173: 1-12
11. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR 2005 Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. J Lab Clin Med 145: 83-87
12. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158
13. Steinberg D 1997 Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272: 20963-20966
14. Stoll LL, McCormick ML, Denning GM, Weintraub NL 2004 Antioxidant effects of statins. Drugs Today (Barc) 40: 975-990
15. Stoll LL, McCormick ML, Denning GM, Weintraub NL 2005 Antioxidant effects of statins. Timely Top Med Cardiovasc Dis 9: E1
16. Stolley PD, Strom BL 1986 Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 39: 489-490
17. Suzumura K, Yasuhara M, Tanaka K, Suzuki T 1999 Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 57: 697-703
18. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R 2003 Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 16: 238-244
19. Whitehead TP, Robinson D, Allaway S, Syms J, Hale A 1995 Effect of red wine ingestion on the antioxidant capacity of serum. Clin Chem 41: 32-35
20. Yoshida H, Ishikawa T, Ayaori M, Shige H, Hosoai H, Nishio E, Tomiyasu K, Yamashita T, Suzukawa M, Nishiwaki M et al 1995 Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. Clin Ther 17: 379-389